BPC-157 & TB-500 for sale
BPC-157 Peptide, also known as Pentadecapeptide BPC-157, or Body Protection Compound 157, originated from a protein found in the human digestive system, has been shown in various studies to help with healing joint, tendon, and muscle tissue, as well as nerve tissue.
TB-500 Peptide, also known as Thymosin beta-4, or TB-4, has been shown to help in the healing process after injury, especially brain and neurological injury. Other TB-500 research has shown it helps with wound healing and with hair growth.
BPC-157 & TB-500 Blend Research
It is a known fact that with increasing age, the ability of the bodily functions to occur at a normal rate decline. This also includes the levels of naturally occurring proteins and the rate at which usual functions govern such as wound healing.
While there are many medications available to beat the lowering rates of the bodily functions, they all come at a price – causing various side effects. This is why peptides are becoming more common and widely used as compared to medications, because peptides stimulate, in some cases replicate, the same body functions in a more ‘natural’ way, causing lesser adverse effects.
Both components in the BPC-157 & TB-500 blend are synthetic peptides, derived from naturally occurring proteins in the human body, which have shown promising results in elevating the wound healing process.
BPC-157 & TB-500 Blend
Both BPC-157 and TB-500 are synthetic polypeptides, where TB-500 is composed of 43 amino acids (1) and BPC-157 is composed of 15 amino acids (2).
TB-500 peptide is the synthetic form of Thymosin beta 4, a naturally occurring protein that induces angiogenesis and elevates the wound healing process (3). Likewise, BPC-157 peptide is the synthetic form of the protein segment derived from the gastric juice found in the body (4). Resembling the naturally occurring proteins, this makes both peptides highly biocompatible and stable in the body.
The history of BPC-157 peptide dates back to the late 1800s when the brain to gut axis was first discovered. During extensive studies at the time, it was discovered how the proteins secreted in the gastric system help to reduce gastric lesions (5) and also in angiogenesis and tendon healing process (6).
On the other hand, TB-500 peptide first came into the picture when the thymosin proteins were discovered in 1964. Until the discovery of the thymosin proteins, the thymus gland was assumed to be a vestigial body organ. It was later after several research studies that it was known that the thymus gland also secretes thymosin beta 4 proteins, which are critical to the wound repair and healing process (7).
How Does BPC-157 & TB-500 Stack Work?
Both BPC-157 & TB-500 generate similar effects in the body i.e., wound healing, tissue repair and angiogenesis.
TB-500 mainly exerts its effects by elevating the levels of actin proteins in the body. TB-500 has a distinct amino acid segment [(17)LKKTETQ(23)] which is responsible for actin binding and the wound healing process (8).
BPC-157 peptide exerts its effect by stimulating the growth hormone receptors. The peptide binds with the receptors and induces cell proliferation. As a result, new tissues composed of collagen are formed, thereby healing the wound faster than usual (4).
What Is so Special About the Blend?
As both TB-500 and BPC-157 peptides demonstrate similar pharmacological effects, when blended together, it maximizes the effects of both – what would otherwise occur with one peptide, will now occur at a better, faster rate when combined.
What makes it more interesting is that several online platforms, where the blend is being sold, names this as a “wolverine peptide stack” – primarily because the stack helps to heal the body speedily, just like a wolverine.
BPC-157 & TB-500 Blend Benefits
The benefits of the BPC-157 & TB-500 peptide blend are:
- Elevate angiogenesis – faster wound healing
- Stimulates tendon, muscle, bone, and ligament healing
- Reduce inflammation
- Decrease in pain levels
- Induce tissue repair
Available Research Studies
There are no research or clinical studies currently available with the blend itself, where both TB-500 and BPC-157 were used in the same treatment or co-administered in the same subject.
However, below listed are the studies demonstrating the wound healing effects of the individual peptides, from which it can be evident how the peptide blend works in the body.
TB-500 and Wound Healing
In this 1999 study (9) the experimentally wounded rats were used as subjects, where half the number of rats were treated with saline and the rest were treated with TB-500 peptide via topical or intraperitoneal route. The main aim of this study was to determine the extent and efficacy of the wound healing abilities of the peptide.
Four days after the treatment, it was determined that the rats treated with TB-500 showed a 41% increment in the re-epithelialization process (i.e., formation of new epithelial cells to resurface the wound). After seven days, the wounds treated with TB-500 had contracted by at least 11% as compared to the saline treated wounds.
Human Volunteers’ Studies
In this 2006 clinical trial (10), 72 volunteers suffering from pressure ulcers were treated with TB-500. The main aim of this randomized, double blind study was to establish the safety and efficacy of thymosin beta 4 (analogous to TB-500) in ulcer treatment.
The volunteers were divided into two groups, where one group was treated with placebo, via topical application, for 84 days and the rest were treated with 3 doses of peptides (0.01% w/w, 0.02% w/w and 0.1% w/w) via topical administration, daily for up to 84 days.
After 84 days, there was an occurrence of wound healing process where the ulcers showed signs of healing. All adverse events were monitored on a weekly basis for 84 days and on day 99, and no mortality cases were reported.
TB-500 Ligament Healing
In this study(11), the medial collateral ligament (MCL) of the rats was transected (cut across) during surgery. All the rats were then treated with 100 microL of fibrin sealing agent, where some rats were also treated with 1 microg of thymosin beta 4.
Four weeks after the surgery, it was noticed that the healing tissues in the peptide treated rats exhibited evenly formed and spaced collagen cells. What’s more, the collagen cells formed in the peptide treated rats were wider as compared to the remaining rats. Thus, it was determined that the peptide promoted healing of the ligaments at a faster and more efficient rate than usual.
BPC-157 Wound Healing
In this study (12), three experimental models of rats were used as subjects where all were experimentally wounded, either acute or chronic wounds. These rats were then divided into two groups, where one was treated with placebo and the other was treated with BC 157 peptide.
After the treatment, all the rats were histologically examined, and it was determined that the rats treated with BPC-157 had a prominently higher number of collagen and blood vessels formed as compared to the placebo treated rats. Consequently, this fact proved that BPC-157 peptide induced angiogenesis and consequent wound healing at a faster rate than usual.
BPC-157 Muscle Healing
This study (13) was conducted on rats with experimentally injured gastrocnemius muscle complex. These rats were initially treated with corticosteroids, namely Methylprednisolone, which led to severe muscular damage in these rats. These rats were then divided into two groups, where one was treated with placebo and the other with BPC-157 via topical and intraperitoneal route of administration daily for up to 14 days.
After the treatment, it was noticed that the BPC-157 treated rats showed complete restoration of their gastric muscles along with its full ability to function efficiently. Whereas, the placebo treated group did not show any significant change to the damaged muscles.
All the above listed studies demonstrate that both BPC-157 & TB-500 promote the healing effects by elevating the levels of collagen, fiber cells and overall rate of angiogenesis. Thus, upon administering the blend, the two peptides exhibit the same effects at a faster, more efficient rate.
That being said, it should also be noted that the clinical trials for both peptides are still underway to collect sufficient data and determine the full potential and scope of the two peptides.
Side Effects of the peptide blend
The common side effects of the peptide stack are as listed below:
- Dry mouth
- Flu like symptoms
- Redness and pain at the site of injection – temporary, at the time of administration
BPC-157 & TB-500 Blend Dosage
Based on the above listed research studies (9,10,13), both BPC-157 & TB-500 are available in liquid dosage forms and have demonstrated successful outcomes when administered topically and intraperitoneally.
As with other medications, the optimal dose of the peptide blend would mainly depend on the patient’s individual and drug profile. As mentioned above, the clinical trials for both peptides are still underway and hence any pre-fixed, optimum blend dosage can be determined then.
Is the peptide blend prohibited in sports?
While BPC-157 is not exclusively prohibited in sports, thymosin beta 4 and its derivatives (namely, TB-500) are included in the List of Prohibited items by World Anti-Doping Agency (WADA)(14).
It is suspected that athletes misuse the TB-500 peptides and use it as a doping agent mainly because of its ability to heal the wounds faster and elevate angiogenesis (3). While BPC-157 is not included in the list yet, it can be safely presumed that it may soon be included in the list once sufficient clinical data on the peptides become available.
BPC-157 & TB-500 are synthetic polypeptides that elevate the rate of wound healing, tissue repair and angiogenesis process.
While the mode of action of both peptides differs, they both exhibit similar effects in the body. TB-500 mainly executes its effects by stimulating and elevating the levels of actin proteins in the body, whereas BPC-157 bind with specific growth hormone receptors and stimulate cell proliferation. Owing to similar pharmacological effects, when both peptides are blended together, they maximize their effects and deliver faster, yet efficient, results.
While many studies and research data are available to demonstrate the individual peptide efficacy, the clinical data for both peptides is not yet fully sufficient. Clinical research on both the peptides continues being conducted to explore full potential and use of the peptides, and subsequently the blend.
1. National Center for Biotechnology Information. “PubChem Compound Summary for CID 132558700, CID 132558700” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/132558700
2. National Center for Biotechnology Information. “PubChem Compound Summary for CID 9941957” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157
3. Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 Nov 23. https://pubmed.ncbi.nlm.nih.gov/23084823/
4. Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/
5. Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC-157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#r1
6. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC-157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:191-6 https://pubmed.ncbi.nlm.nih.gov/20388964/
7. Julia Parmley, A Life-Saving Discovery, January 04, 2010. https://gwhtoday.gwu.edu/life-saving-discovery
8. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. PMID: 18480812. https://pubmed.ncbi.nlm.nih.gov/18480812/
9. Katherine M. Malinda et.al, Thymosin β4 Accelerates Wound Healing, Journal of Investigative Dermatology, Volume 113, Issue 3, 1999, Pages 364-368, ISSN 0022-202X, https://www.sciencedirect.com/science/article/pii/S0022202X15405950
10. Study of Thymosin Beta 4 in Patients With Pressure Ulcers. https://www.clinicaltrials.gov/ct2/show/NCT00382174
11. Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, Jiang D. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013 Jun 10;184:1-5. doi: 10.1016/j.regpep.2013.03.026. https://pubmed.ncbi.nlm.nih.gov/23523891/
12. S Seiwerth, et al. “BPC-157’s effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/
13. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC-157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676. https://pubmed.ncbi.nlm.nih.gov/20190676/
14. List of prohibited items (WADA) https://www.wada-ama.org/en/
For an overall TB-500 Review and its potential healing benefits, especially with tendon, ligament and muscle injuries, read our TB-500 (Thymosin beta 4) – Review, Benefits, Side Effects blog post.
NOTE: These products are intended for laboratory research use only. BPC-157 & TB-500 stack (10mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.